Humacyte (HUMA) - 72.89% Below 52-Week High: Buy or Wait?

Stock Details

Humacyte, Inc. (HUMA), a prominent company in the healthcare sector within the biotechnology industry, is based in United States and primarily trades on the NMS.Currently, the stock is trading at $0.77. Over the past 52 weeks, it has ranged between $0.55 and $2.84. This places the current price at 27.1% of its 52-week high and 40.8% above its 52-week low. Recent trading volume was recorded at 9,475,352. The 14-day Relative Strength Index (RSI) stands at 37.90, suggesting neutral conditions. The stock is currently trading below its 50-day moving average of $0.99 by 22.22%. Similarly, it is below its 200-day moving average of $1.16 by 33.62%. The MACD histogram is -0.03, indicating bearish momentum (MACD Line: -0.11, Signal Line: -0.08).

Fundamentals

Valuation Metrics

P/E Ratio (TTM)

N/A

Forward P/E

-2.96

Price to Book

13.65

EV/EBITDA

-1.67

EPS (TTM)

-$0.63

Price to Sales

94.96

Beta

2.52

More volatile than market

Q:How is HUMA valued relative to its earnings and growth?

Valuation data is not available for this stock.

Q:What is HUMA's risk profile compared to the market?

With a beta of 2.52, Humacyte, Inc. is significantly more volatile than the market. For every 10% market move, this stock tends to move 25% in the same direction. Higher beta stocks offer greater potential returns but with increased risk. The price-to-book ratio of 13.65 shows investors value the company above its book value, which often reflects intangible assets or growth prospects.

Performance & Growth

Profit Margin

0.00%

Operating Margin

-5704.04%

EBITDA

$-105,185,000

Return on Equity

-409.47%

Return on Assets

-51.48%

Revenue Growth (YoY)

-4.30%

Q:How profitable and efficient is HUMA's business model?

0 The operating margin of -5704.04% reveals how efficiently the company runs its core business operations before interest and taxes. With ROE at -409.47% and ROA at -51.48%, the company achieves moderate returns on invested capital.

Q:What are HUMA's recent growth trends?

Humacyte, Inc.'s revenue declined by 4.30% year-over-year, indicating challenges in maintaining sales momentum. This contraction may reflect market headwinds, competitive pressures, or strategic transitions. These growth metrics should be evaluated against Biotechnology industry averages for proper context.

Company Size & Market

Market Cap

$191.4M

Revenue (TTM)

$2.02M

Revenue/Share (TTM)

$0.01

Shares Outstanding

269.64M

Book Value/Share

$0.05

Asset Type

EQUITY

Q:What is HUMA's market capitalization and position?

Humacyte, Inc. has a market capitalization of $191.4M, classifying it as a small-cap stock (under $2B). Small-caps offer significant growth potential but come with higher volatility and risk. They can be more sensitive to economic conditions but may provide outsized returns if successful. With 269.64M shares outstanding, the company's ownership is relatively concentrated. As a participant in the Biotechnology industry, it competes with other firms in this sector.

Q:How does HUMA's price compare to its book value?

Humacyte, Inc.'s book value per share is $0.05, while the current stock price is $0.77, resulting in a price-to-book (P/B) ratio of 14.81. This high P/B ratio indicates significant intangible assets, strong brand value, or high growth expectations. Technology and consumer brand companies often trade at elevated P/B ratios due to intellectual property and competitive advantages not reflected on the balance sheet. As EQUITY, this represents a specific type of security.

Analyst Ratings

Analyst Target Price

$2.05

166.23% upside potential

Analyst Recommendations

Strong Buy

Buy

Hold

Sell

Strong Sell

Q:How reliable are analyst predictions for HUMA?

7 analysts cover HUMA with 86% recommending buy/strong buy ratings. Analyst predictions have mixed reliability - studies show consensus rarely beats market returns consistently. The strong bullish consensus may already be priced in. The consensus target of $2.05 implies 166.2% upside, but targets are often adjusted to follow price moves rather than predict them.

Q:What is the Wall Street consensus on HUMA?

Current analyst recommendations:1 Strong Buy, 5 Buy, 1 Hold, 00The bullish tilt suggests optimism about future prospects, though investors should conduct independent research.Remember that analyst opinions often lag price movements and can be influenced by investment banking relationships.

Fundamentals last updated: Jul 6, 2026, 02:17 AM

Technical Indicators

RSI (14-day)

37.90

Neutral

50-Day Moving Average

$0.99

-22.22% below MA-50

200-Day Moving Average

$1.16

-33.62% below MA-200

MACD Line

-0.11

MACD Signal

-0.08

MACD Histogram

-0.03

Bearish

Q:What does HUMA's RSI value tell investors?

The RSI (Relative Strength Index) for HUMA is currently 37.90, indicating the stock is showing bearish momentum (30-40 range). Selling pressure is evident but not extreme. This often occurs during pullbacks in uptrends or early stages of downtrends. Combined with the price being below the 50-day moving average, this confirms bearish conditions.

Q:How should traders interpret HUMA's MACD and moving average crossovers?

MACD analysis shows the MACD line at -0.11 below the signal line at -0.08, with histogram at -0.03. This bearish crossover indicates downward pressure. The narrow histogram suggests a potential trend change ahead. The 50-day MA ($0.99) is below the 200-day MA ($1.16), forming a death cross pattern that often warns of extended weakness. Price is currently below both MAs, confirming weakness.

Indicators last updated: Jul 6, 2026, 12:39 AM

Humacyte, Inc. (HUMA) Stock